MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Response to treatment in Type 2 Diabetes is highly variable; the same medicine may have
little effect in one person but a large effect in another. Understanding mechanisms of
altered response to treatment could aid treatment selection and assist the design of new
medications with lower nonresponse rates.
This study will examine the physiological mechanisms and potential clinical/biomarker
predictors of altered response to sulphonylurea and DPPIV inhibitor glucose lowering
medication and answer fundamental methodological questions for the future study of variation
in treatment response in Type 2 Diabetes. Participants will withdraw sulphonylurea therapy
for up to 2 weeks with assessment of baseline characteristics and glycaemic response.
Participants will then enter an optional extension where they receive sulphonylurea or DPPIV
inhibitor therapy in crossover fashion.
Phase:
Phase 4
Details
Lead Sponsor:
NIHR Exeter Clinical Research Facility Royal Devon and Exeter NHS Foundation Trust
Collaborator:
University of Exeter
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Gliclazide Sitagliptin Phosphate